PL370221A1 - 2-oxazolamines and their use as 5-ht2b receptor antagonists - Google Patents
2-oxazolamines and their use as 5-ht2b receptor antagonistsInfo
- Publication number
- PL370221A1 PL370221A1 PL03370221A PL37022103A PL370221A1 PL 370221 A1 PL370221 A1 PL 370221A1 PL 03370221 A PL03370221 A PL 03370221A PL 37022103 A PL37022103 A PL 37022103A PL 370221 A1 PL370221 A1 PL 370221A1
- Authority
- PL
- Poland
- Prior art keywords
- oxazolamines
- receptor antagonists
- ht2b receptor
- ht2b
- antagonists
- Prior art date
Links
- ACTKAGSPIFDCMF-UHFFFAOYSA-N 1,3-oxazol-2-amine Chemical class NC1=NC=CO1 ACTKAGSPIFDCMF-UHFFFAOYSA-N 0.000 title 1
- 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 title 1
- 108010072584 5-HT2B Serotonin Receptor Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0203412.2A GB0203412D0 (en) | 2002-02-13 | 2002-02-13 | 5-HT 2B receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL370221A1 true PL370221A1 (en) | 2005-05-16 |
Family
ID=9930999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03370221A PL370221A1 (en) | 2002-02-13 | 2003-02-11 | 2-oxazolamines and their use as 5-ht2b receptor antagonists |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7429607B2 (enExample) |
| EP (1) | EP1474140B1 (enExample) |
| JP (1) | JP4439266B2 (enExample) |
| KR (1) | KR20040084905A (enExample) |
| CN (1) | CN1633291A (enExample) |
| AU (1) | AU2003207297B2 (enExample) |
| CA (1) | CA2472762A1 (enExample) |
| DE (1) | DE60317632T2 (enExample) |
| EA (1) | EA200401077A1 (enExample) |
| GB (1) | GB0203412D0 (enExample) |
| IL (1) | IL163110A (enExample) |
| MX (1) | MXPA04007738A (enExample) |
| NO (1) | NO327465B1 (enExample) |
| NZ (1) | NZ534539A (enExample) |
| PL (1) | PL370221A1 (enExample) |
| WO (1) | WO2003068226A1 (enExample) |
| ZA (1) | ZA200406010B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1299948B1 (it) | 1998-04-02 | 2000-04-04 | Azionaria Costruzioni Acma Spa | Metodo e dispositivo per la formazione di gruppi di articoli appiattiti. |
| US20050176791A1 (en) * | 2002-02-13 | 2005-08-11 | Oxford Alexander W. | 5-HT2B receptor antagonists |
| JP2006528617A (ja) * | 2003-07-24 | 2006-12-21 | ファーマジーン ラボラトリーズ リミテッド | ５−ｈｔ２ｂ受容体アンタゴニスト |
| WO2005079845A1 (ja) | 2004-02-20 | 2005-09-01 | Astellas Pharma Inc. | 片頭痛予防薬 |
| SE0400850D0 (sv) * | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| WO2005097113A2 (en) * | 2004-04-08 | 2005-10-20 | Pharmagene Laboratories Limited | 5-ht2b receptor antagonists |
| PL1797038T3 (pl) | 2004-09-29 | 2012-11-30 | Bayer Healthcare Llc | Termodynamicznie trwała postać tosylanu bay 43-9006 |
| WO2014085413A1 (en) * | 2012-11-28 | 2014-06-05 | Temple University - Of The Commonwealth System Of Higher Education | Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2b activity modulators |
| KR101592068B1 (ko) | 2013-11-08 | 2016-02-05 | 순천향대학교 산학협력단 | 플라즈마 아포리포프로테인 h를 포함하는 아스피린 과민성 호흡계 질환 및 아스피린 내성 천식 구별 진단용 마커 및 구별 진단용 키트 |
| CN116789549A (zh) * | 2023-06-16 | 2023-09-22 | 山东科源化工有限公司 | 一种羟基乙酸乙烯酯的制备工艺 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0658559A1 (de) * | 1993-12-14 | 1995-06-21 | Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. | Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren |
| WO1995024200A1 (en) | 1994-03-11 | 1995-09-14 | Eli Lilly And Company | Method for treating 5ht2b receptor related conditions |
| US5663178A (en) | 1995-02-06 | 1997-09-02 | Eli Lilly And Company | Tetrahydro-beta carbolines |
| ATE227710T1 (de) * | 1996-04-03 | 2002-11-15 | Takeda Chemical Industries Ltd | Oxazole derivate,ihre herstellung und verwendung |
| US5958934A (en) | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
| US5952331A (en) | 1996-05-23 | 1999-09-14 | Syntex (Usa) Inc. | Aryl pyrimidine derivatives |
| TW440563B (en) * | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
| WO2000023444A1 (en) * | 1998-10-21 | 2000-04-27 | Abbott Laboratories | 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
| EP1200093B1 (en) | 1999-07-30 | 2003-09-24 | Pharmagene Laboratories Ltd | Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders |
| AR035016A1 (es) * | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
-
2002
- 2002-02-13 GB GBGB0203412.2A patent/GB0203412D0/en not_active Ceased
-
2003
- 2003-02-11 DE DE60317632T patent/DE60317632T2/de not_active Expired - Lifetime
- 2003-02-11 WO PCT/GB2003/000552 patent/WO2003068226A1/en not_active Ceased
- 2003-02-11 NZ NZ534539A patent/NZ534539A/en not_active IP Right Cessation
- 2003-02-11 KR KR10-2004-7012479A patent/KR20040084905A/ko not_active Ceased
- 2003-02-11 CN CNA038039532A patent/CN1633291A/zh active Pending
- 2003-02-11 AU AU2003207297A patent/AU2003207297B2/en not_active Ceased
- 2003-02-11 PL PL03370221A patent/PL370221A1/xx not_active IP Right Cessation
- 2003-02-11 EP EP03704768A patent/EP1474140B1/en not_active Expired - Lifetime
- 2003-02-11 JP JP2003567408A patent/JP4439266B2/ja not_active Expired - Fee Related
- 2003-02-11 EA EA200401077A patent/EA200401077A1/ru unknown
- 2003-02-11 MX MXPA04007738A patent/MXPA04007738A/es active IP Right Grant
- 2003-02-11 CA CA002472762A patent/CA2472762A1/en not_active Abandoned
- 2003-02-12 US US10/364,672 patent/US7429607B2/en not_active Expired - Fee Related
-
2004
- 2004-07-20 IL IL163110A patent/IL163110A/en not_active IP Right Cessation
- 2004-07-28 ZA ZA200406010A patent/ZA200406010B/en unknown
- 2004-09-10 NO NO20043799A patent/NO327465B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200406010B (en) | 2005-06-08 |
| DE60317632D1 (de) | 2008-01-03 |
| JP2005528341A (ja) | 2005-09-22 |
| EP1474140A1 (en) | 2004-11-10 |
| US20040010022A1 (en) | 2004-01-15 |
| MXPA04007738A (es) | 2004-10-15 |
| NZ534539A (en) | 2006-02-24 |
| US7429607B2 (en) | 2008-09-30 |
| NO327465B1 (no) | 2009-07-06 |
| EA200401077A1 (ru) | 2005-06-30 |
| KR20040084905A (ko) | 2004-10-06 |
| GB0203412D0 (en) | 2002-04-03 |
| WO2003068226A1 (en) | 2003-08-21 |
| CN1633291A (zh) | 2005-06-29 |
| EP1474140B1 (en) | 2007-11-21 |
| CA2472762A1 (en) | 2003-08-21 |
| IL163110A (en) | 2010-12-30 |
| AU2003207297A2 (en) | 2003-09-04 |
| JP4439266B2 (ja) | 2010-03-24 |
| DE60317632T2 (de) | 2008-10-30 |
| NO20043799L (no) | 2004-09-10 |
| AU2003207297A1 (en) | 2003-09-04 |
| AU2003207297B2 (en) | 2008-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL162825A0 (en) | Fluoro substituted cycloalkanoindoles and their use asprotaglandin d2 receptor antagonists | |
| IL165841A0 (en) | Mchir antagonists | |
| IL155712A0 (en) | Aminothiazoles and their use as adenosine receptor antagonists | |
| IL152700A0 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists | |
| IL183541A0 (en) | Toll like receptor 3 antagonists, methods and uses | |
| IL152701A0 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| IL169336A0 (en) | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | |
| IL175084A0 (en) | Antagonists of the bradykinin b1 receptor | |
| AU2003291959A8 (en) | Novel glucagon antagonists | |
| IL176350A0 (en) | Crf receptor antagonists and methods relating thereto | |
| PL378753A1 (pl) | Antagoniści receptora CCR-3 | |
| AU2003267088A8 (en) | Chemokine receptor antagonists as therapeutic agents | |
| PL370221A1 (en) | 2-oxazolamines and their use as 5-ht2b receptor antagonists | |
| IL173746A0 (en) | Modified il-4 mutein receptor antagonists | |
| PL1641787T3 (pl) | Podstawione diketopiperazyny i ich zastosowanie jako antagonistów oksytocyny | |
| GB0226227D0 (en) | Receptors | |
| SG131946A1 (en) | Ccr3 receptor antagonists | |
| IL169337A0 (en) | Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | |
| ZA200705206B (en) | Toll like receptor 3 antagonists, methods and uses | |
| IL162534A0 (en) | Novel alkansulfonamides as endotheline antagonists | |
| GB0302094D0 (en) | EP4 receptor antagonists | |
| AU2003300867A8 (en) | Uses of the snorf207 receptor | |
| GB0215389D0 (en) | Receptor | |
| IL158063A0 (en) | Crf receptor antagonists | |
| GB0223399D0 (en) | Receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VOID | Decisions declaring the decisions on the grant of the patent lapsed |